journal
MENU ▼
Read by QxMD icon Read
search

Rheumatology and Therapy

journal
https://www.readbyqxmd.com/read/29761420/long-term-radiographic-and-patient-reported-outcomes-in-patients-with-rheumatoid-arthritis-treated-with-tofacitinib-oral-start-and-oral-scan-post-hoc-analyses
#1
Vibeke Strand, Arthur Kavanaugh, Alan J Kivitz, Désirée van der Heijde, Kenneth Kwok, Ermeg Akylbekova, Arif Soonasra, Mark Snyder, Carol Connell, Eustratios Bananis, Josef S Smolen
INTRODUCTION: Here we examine the relationship between achieving different levels of disease activity with tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis), long-term structural progression, and patient-reported physical function. METHODS: This was a post hoc analysis of two 24-month, phase III randomized controlled trials in methotrexate (MTX)-naïve (ORAL Start [NCT01039688]) or MTX-inadequate responder (IR) patients (ORAL Scan [NCT00847613]) receiving tofacitinib 5 or 10 mg twice daily as either monotherapy or with background MTX...
May 14, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29752705/risk-associated-with-cumulative-oral-glucocorticoid-use-in-patients-with-giant-cell-arteritis-in-real-world-databases-from-the-usa-and-uk
#2
Sara Gale, Jessica C Wilson, Jenny Chia, Huong Trinh, Katie Tuckwell, Neil Collinson, Sophie Dimonaco, Susan Jick, Christoph Meier, Shalini V Mohan, Khaled Sarsour
INTRODUCTION: Treatment of giant cell arteritis (GCA) involves immediate initiation of high-dose glucocorticoid therapy with slow tapering of the dose over many months. Chronic exposure to glucocorticoids is associated with serious comorbidities. The objective of this analysis was to determine the glucocorticoid exposure and risk of glucocorticoid-related adverse events (AEs) in real-world patients with GCA. METHODS: Data from the Truven Healthcare MarketScan® database (from January 1, 2000, to June 30, 2015) and the Clinical Practice Research Datalink (CPRD; from January 1, 1995, to August 31, 2013) were used to retrospectively analyze patients aged ≥ 50 years with GCA in the USA and UK, respectively...
May 11, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29725991/retreatment-with-pegloticase-after-a-gap-in-therapy-in-patients-with-gout-a-report-of-four-cases
#3
Allan H Morton, Tony Hosey, Brian LaMoreaux
INTRODUCTION: Pegloticase, a potent uricolytic biologic enzyme, has been shown to be an effective therapeutic option in patients with uncontrolled gout. However, there are limited data on clinical response after a gap in therapy and retreatment with pegloticase. CASE SERIES: This report describes four patients with chronic gout who were successfully managed with pegloticase and were retreated following a gap in therapy. Patient charts from a practice-based rheumatology clinic were retrospectively analyzed; four male patients, aged 70-75 years, with chronic gout and a more than 4-week gap in pegloticase therapy were reviewed...
May 3, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29680881/baricitinib-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-conventional-disease-modifying-antirheumatic-drugs-in-united-states-and-rest-of-world-a-subset-analysis
#4
Alvin F Wells, Maria Greenwald, John D Bradley, Jahangir Alam, Vipin Arora, Cynthia E Kartman
INTRODUCTION: This article evaluates the efficacy and safety of baricitinib 4 mg versus placebo in United States including Puerto Rico (US) and rest of the world (ROW) subpopulations using data pooled from RA-BEAM and RA-BUILD, which enrolled patients with moderate-to-severe adult-onset rheumatoid arthritis (RA). METHODS: In RA-BEAM, patients with an inadequate response (IR) to methotrexate, at least one X-ray erosion, and high sensitivity C-reactive protein (hsCRP) ≥ 6 mg/L were randomized to placebo or orally administered baricitinib 4 mg daily or subcutaneously administered adalimumab 40 mg every other week...
April 21, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29633196/impact-of-the-adalimumab-patient-support-program-on-clinical-outcomes-in-ankylosing-spondylitis-results-from-the-companion-study
#5
Louis Bessette, Gerald Lebovic, Brad Millson, Katia Charland, Krishna Donepudi, Tania Gaetano, Valencia Remple, Martin G Latour, Sandra Gazel, Marie-Claude Laliberté, Carter Thorne
INTRODUCTION: Adalimumab (ADA) is a tumor necrosis factor (TNF)-alpha inhibitor indicated for the treatment of inflammatory autoimmune diseases, including ankylosing spondylitis (AS). Patients receiving ADA in Canada are eligible to enroll in the AbbVie Care™ patient support program (AC-PSP), which provides personalized services, including care coach calls (CCCs). We estimated the likelihood of controlled disease in a cohort of AS patients treated with ADA enrolled in the AC-PSP and who received CCCs versus those who did not...
April 9, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29616498/quality-of-care-in-rheumatoid-disease-from-the-clinician-perspective-a-modified-delphi-panel-approach
#6
Finbar O'Shea, Peter C Taylor, Gavin Dickie, Andrew Yaworsky, Benjamin Banderas, Sumesh Kachroo
INTRODUCTION: To establish clinical consensus on important and relevant quality-of-care (QoC) attributes in rheumatic disease (RD) treatment that may improve treatment outcomes and guide best practices. METHODS: Twenty-three QoC attributes were identified in a literature review. Fifteen European-based clinicians were selected based on their contributions to RD guidelines, publications, and patient care. A three-round (an interview round and two web-based rounds) modified Delphi panel was conducted to reach consensus and finalize a QoC attribute list...
April 3, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29605841/secukinumab-versus-adalimumab-for-psoriatic-arthritis-comparative-effectiveness-up-to-48-weeks-using-a-matching-adjusted-indirect-comparison
#7
Peter Nash, Iain B McInnes, Philip J Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, Steffen M Jugl
INTRODUCTION: Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. METHODS: Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs...
March 31, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29574622/similar-improvements-in-patient-reported-outcomes-among-rheumatoid-arthritis-patients-treated-with-two-different-doses-of-methotrexate-in-combination-with-adalimumab-results-from-the-musica-trial
#8
Gurjit S Kaeley, Daryl K MacCarter, Janak R Goyal, Shufang Liu, Kun Chen, Jennifer Griffith, Hartmut Kupper, Vishvas Garg, Jasmina Kalabic
INTRODUCTION: In patients with rheumatoid arthritis (RA), combination treatment with methotrexate (MTX) and adalimumab is more effective than MTX monotherapy. From the patients' perspective, the impact of reduced MTX doses upon initiating adalimumab is not known. The objective was to evaluate the effects of low and high MTX doses in combination with adalimumab initiation on patient-reported outcomes (PROs), in MTX-inadequate responders (MTX-IR) with moderate-to-severe RA. METHODS: MUSICA was a randomized, double-blind, controlled trial evaluating the efficacy of 7...
March 24, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29633197/cost-effectiveness-analysis-of-golimumab-in-the-treatment-of-non-radiographic-axial-spondyloarthritis-in-scotland
#9
Rebekah H Borse, Sumesh Kachroo, Chloe Brown, Eilish McCann, Ralph P Insinga
INTRODUCTION: The aim of this study is to assess the cost-effectiveness of golimumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) vs. conventional therapy and other tumor necrosis factor inhibitors from the Scottish payer perspective. METHODS: A model comprising a short-term decision tree and a long-term Markov model was developed to compare cost-effectiveness (incremental costs per quality-adjusted life-year [QALY]) for patients in Scotland with nr-axSpA treated by conventional therapy, adalimumab, certolizumab pegol, etanercept, or golimumab for a lifetime period...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29536378/a-case-report-of-chikungunya-fever-rheumatoid-arthritis-and-felty-s-syndrome
#10
José Kennedy Amaral, Robert T Schoen
INTRODUCTION: Chronic chikungunya (CHIK) arthritis, an inflammatory arthritis, often follows acute CHIK fever (CHIKF), a viral infection. The pathogenesis of chronic CHIK arthritis is poorly characterized, but may resemble other forms of inflammatory arthritis. Clinically, chronic CHIK arthritis sometimes mimics rheumatoid arthritis (RA). CASE REPORT: We report a patient with well-characterized CHIKF followed 2 months later by chronic CHIK arthritis not only resembling RA clinically, but also associated with RA biomarkers and extra-articular features, including Felty's syndrome (FS)...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29524120/a-beacon-in-the-dark-canakinumab-a-new-therapeutic-perspective-in-chronic-tophaceous-gout
#11
Daniela Marotto, Antonella De Santis, Donatella Chessa, Davide Firinu, Stefano Del Giacco
Gout is the most common form of arthritis in adults. It is often associated with other comorbidities, which contraindicate the use of conventional therapies. The discovery of the role of interleukin-1β (IL-1β) in orchestrating the monosodium urate crystal-induced inflammatory response offered new therapeutic prospects to refractory patients, or to those in whom standard therapies are contraindicated. This paper describes a clinical case of a 65-year-old man with chronic tophaceous gouty arthropathy and subintrant flares, who had comorbidities contraindicating the use of conventional gout therapies-to which he did not respond-who was treated with canakinumab, a monoclonal selective inhibitor of IL-1β...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29516402/role-of-human-leukocyte-antigens-hla-in-autoimmune-diseases
#12
REVIEW
Gergely Bodis, Victoria Toth, Andreas Schwarting
Since the discovery of HLA 60 years ago, it has contributed to the understanding of the immune system as well as of the pathogenesis of several diseases. Aside from its essential role in determining donor-recipient immune compatibility in organ transplantation, HLA genotyping is meanwhile performed routinely as part of the diagnostic work-up of certain autoimmune diseases. Considering the ability of HLA to influence thymic selection as well as peripheral anergy of T cells, its role in the pathogenesis of autoimmunity is understandable...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29502236/a-review-of-recent-advances-using-tocilizumab-in-the-treatment-of-rheumatic-diseases
#13
REVIEW
Andrea Rubbert-Roth, Daniel E Furst, Jan Michael Nebesky, Angela Jin, Erhan Berber
Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid arthritis (RA), Castleman's disease, polyarticular and systemic juvenile idiopathic arthritis, and, most recently, giant cell arteritis as well as for the treatment of chimeric antigen receptor T cell therapy-induced cytokine release syndrome. The global clinical development program for TCZ provides a wealth of clinical data on intravenous TCZ, and more recent studies in patients with RA have provided evidence characterizing the role of intravenous TCZ as monotherapy in early disease and led to the introduction of a subcutaneous formulation of TCZ...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29500791/safety-effectiveness-and-treatment-persistence-of-golimumab-in-elderly-patients-with-rheumatoid-arthritis-in-real-world-clinical-practice-in-japan
#14
Masateru Okazaki, Hisanori Kobayashi, Hirohito Shimizu, Yutaka Ishii, Tsutomu Yajima, Masayoshi Kanbori
INTRODUCTION: Golimumab has been proven as an effective treatment for rheumatoid arthritis in clinical trials. However, there is a scarcity of data regarding its use in elderly patients in a real-world setting. This study aims to evaluate the safety, effectiveness, and treatment persistence of golimumab in elderly Japanese patients (≥ 75 years) with rheumatoid arthritis. METHODS: This study was a post hoc analysis of post-marketing surveillance data on 5137 Japanese patients with active rheumatoid arthritis who received golimumab for 24 weeks...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29480358/living-with-juvenile-idiopathic-arthritis-parent-and-physician-perspectives
#15
Shelly Heath-Watson, Sangeeta Sule
This article, co-authored by a parent of a child with juvenile idiopathic arthritis (JIA) and his pediatric rheumatologist, discusses the parent's experience of having a child with JIA from diagnosis through living day-to-day with the disease.
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29480357/maintenance-of-remission-with-etanercept-dmard-combination-therapy-compared-with-dmards-alone-in-african-and-middle-eastern-patients-with-active-rheumatoid-arthritis
#16
Hassan Bassiouni, Catherine Elizabeth Spargo, Bonnie Vlahos, Heather E Jones, Ron Pedersen, Khalid Shirazy
INTRODUCTION: To compare etanercept (ETN) and placebo (PBO) for maintaining low disease activity (LDA) achieved with ETN in patients with rheumatoid arthritis (RA) from Africa and the Middle East. METHODS: In this subset analysis of the Treat-to-Target trial (ClinicalTrials.gov identifier NCT01981473), 53 adult patients with moderate-to-severe RA nonresponsive to methotrexate were treated with 50 mg ETN/week for 24 weeks (Period 1). Patients achieving LDA were randomized to continue ETN treatment or switched to PBO for an additional 28 weeks (Period 2)...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29470835/costs-of-disease-relapses-among-individuals-with-granulomatosis-with-polyangiitis-or-microscopic-polyangiitis-in-the-united-states
#17
Amanda M Kong, Gilwan Kim, Margaret Michalska, Jennie H Best
INTRODUCTION: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are two related forms of systemic vasculitis. Patients with these conditions often experience relapses affecting various body systems. Here we describe rates of relapse and review healthcare costs resulting from relapse among patients with GPA/MPA. METHODS: Two groups of patients with GPA and MPA were selected from the MarketScan claims databases between 2011 and 2013 based on diagnosis codes...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29470834/worldwide-3-year-post-marketing-surveillance-experience-with-tofacitinib-in-rheumatoid-arthritis
#18
Stanley Cohen, Jeffrey R Curtis, Ryan DeMasi, Yan Chen, Haiyun Fan, Arif Soonasra, Roy Fleischmann
INTRODUCTION: Post-marketing surveillance (PMS) is an integral part of monitoring adverse events (AEs) following approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). An analysis of PMS reports was conducted to evaluate the safety of tofacitinib in a post-marketing setting. METHODS: Worldwide tofacitinib PMS data received in the Pfizer safety database from November 6, 2012 (first marketing authorization of tofacitinib) to November 5, 2015 were analyzed...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29470833/cost-of-depression-in-japanese-patients-with-rheumatoid-arthritis-evidence-from-administrative-data
#19
Florent Guelfucci, Yuko Kaneko, Jörg Mahlich, Rosarin Sruamsiri
INTRODUCTION: To determine the cost of depression comorbidity among Japanese adults with rheumatoid arthritis (RA). METHODS: A retrospective database study of 8968 patients diagnosed with RA between 2010 and 2015 and treated with any RA medication was conducted. Health care utilization characteristics were compared between patients with and without a comorbidity of depression. Propensity score matching was applied to ensure a balanced comparison between the two cohorts...
June 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29470832/real-world-treatment-patterns-for-golimumab-and-concomitant-medications-in-japanese-rheumatoid-arthritis-patients
#20
Masateru Okazaki, Hisanori Kobayashi, Yutaka Ishii, Masayoshi Kanbori, Tsutomu Yajima
INTRODUCTION: The aim of this study was to investigate real-world treatment patterns for use of golimumab and concomitant medications in Japanese patients with rheumatoid arthritis. METHODS: This study was a post hoc retrospective analysis from post-marketing surveillance data on 2350 Japanese patients with moderate/severe rheumatoid arthritis who received golimumab for 24 weeks. The study population was divided based on initiation treatment or dose adjustment patterns with golimumab, methotrexate, or oral glucocorticoids...
June 2018: Rheumatology and Therapy
journal
journal
53766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"